Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus‐related cirrhosis: a meta‐analysis
Background: The role of interferon in the prevention of hepatocellular carcinoma remains controversial. Aim: In this meta‐analysis we evaluated the hepatocellular carcinoma incidence in interferon‐treated and ‐untreated patients with hepatitis C virus‐related cirrhosis. Methods: Eleven studies with...
Gespeichert in:
| Veröffentlicht in: | Alimentary pharmacology & therapeutics 2001-05, Vol.15 (5), p.689-698 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 698 |
|---|---|
| container_issue | 5 |
| container_start_page | 689 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 15 |
| creator | Papatheodoridis, G. V. Papadimitropoulos, V. C. Hadziyannis, S. J. |
| description | Background:
The role of interferon in the prevention of hepatocellular carcinoma remains controversial.
Aim:
In this meta‐analysis we evaluated the hepatocellular carcinoma incidence in interferon‐treated and ‐untreated patients with hepatitis C virus‐related cirrhosis.
Methods:
Eleven studies with 2178 patients were found to fulfil our inclusion criteria. The pooled odds ratio (OR) and 95% confidence intervals (CI) were calculated from the raw study data.
Results:
Hepatocellular carcinoma development was significantly more frequent in untreated (21.5%) than in interferon‐treated patients (8.2%; OR: 3.0, 95% CI: 2.3–3.9). In the five studies reporting hepatocellular carcinoma incidence in patients with and without sustained response to interferon, hepatocellular carcinoma was detected at a much higher rate in patients without (9%) than with a sustained response (0.9%; OR: 3.7, 95% CI: 1.7–7.8). Moreover, hepatocellular carcinoma developed significantly more frequently in the untreated patients than in the non‐sustained responders (OR: 2.7, 95% CI: 1.9–3.9). The benefit from interferon on hepatocellular carcinoma incidence was not influenced by the study type (prospective or retrospective), the follow‐up duration, or the study origin.
Conclusions:
Interferon therapy significantly reduces the hepatocellular carcinoma risk in patients with hepatitis C virus cirrhosis. Hepatocellular carcinoma development becomes almost negligible among sustained responders, but a reduction in hepatocellular carcinoma incidence is also achieved even in the non‐sustained responders. |
| doi_str_mv | 10.1046/j.1365-2036.2001.00979.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70838569</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70838569</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4429-aeeab42b8192868d6f37b73c92f366a0111875042a6623f81ea4453a815e36f63</originalsourceid><addsrcrecordid>eNqNkUtuFDEQhi0EIkPgCsgSErtu_Oh224hNNAoPKRIswtqq8ZQ1HvVjsLuTzI4jsOGCOUnc6VHYsqpS_V9VqeonhHJWclapD_uSS1UXgklVCsZ4yZhpTHn3jKyehOdkxYQyhdBcnpFXKe0ZY6ph4iU541wKLZRckb-X3qMb6eBp6EeMHuPQ03GHEQ5HuqR0izfYDocO-0dwhwcYB4dtO7UQqYPoQj90kCfQrISMJXobxt1ChjEkuqY3IU7p_vefiC2MuKUuxLgbUkgfKdAOR8ga9NAec-k1eeGhTfjmFM_Jz8-X1-uvxdX3L9_WF1eFqyphCkCETSU2mhuhld4qL5tNI50RXioFjHOum5pVApQS0muOUFW1BM1rlMoreU7eL3MPcfg1YRptF9J8GPQ4TMk2TEtdK5NBvYAuDilF9PYQQwfxaDmzsyV2b-fP2_nzdrbEPlpi73Lr29OOadPh9l_jyYMMvDsBkBy0PkLvQnrijDKm4pn6tFC3ocXjf6-3Fz-ucyIfAIBAqwM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70838569</pqid></control><display><type>article</type><title>Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus‐related cirrhosis: a meta‐analysis</title><source>MEDLINE</source><source>IngentaConnect Free/Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Papatheodoridis, G. V. ; Papadimitropoulos, V. C. ; Hadziyannis, S. J.</creator><creatorcontrib>Papatheodoridis, G. V. ; Papadimitropoulos, V. C. ; Hadziyannis, S. J.</creatorcontrib><description>Background:
The role of interferon in the prevention of hepatocellular carcinoma remains controversial.
Aim:
In this meta‐analysis we evaluated the hepatocellular carcinoma incidence in interferon‐treated and ‐untreated patients with hepatitis C virus‐related cirrhosis.
Methods:
Eleven studies with 2178 patients were found to fulfil our inclusion criteria. The pooled odds ratio (OR) and 95% confidence intervals (CI) were calculated from the raw study data.
Results:
Hepatocellular carcinoma development was significantly more frequent in untreated (21.5%) than in interferon‐treated patients (8.2%; OR: 3.0, 95% CI: 2.3–3.9). In the five studies reporting hepatocellular carcinoma incidence in patients with and without sustained response to interferon, hepatocellular carcinoma was detected at a much higher rate in patients without (9%) than with a sustained response (0.9%; OR: 3.7, 95% CI: 1.7–7.8). Moreover, hepatocellular carcinoma developed significantly more frequently in the untreated patients than in the non‐sustained responders (OR: 2.7, 95% CI: 1.9–3.9). The benefit from interferon on hepatocellular carcinoma incidence was not influenced by the study type (prospective or retrospective), the follow‐up duration, or the study origin.
Conclusions:
Interferon therapy significantly reduces the hepatocellular carcinoma risk in patients with hepatitis C virus cirrhosis. Hepatocellular carcinoma development becomes almost negligible among sustained responders, but a reduction in hepatocellular carcinoma incidence is also achieved even in the non‐sustained responders.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1046/j.1365-2036.2001.00979.x</identifier><identifier>PMID: 11328263</identifier><language>eng</language><publisher>Oxford UK: Blackwell Science Ltd</publisher><subject>Antineoplastic agents ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - pathology ; Chemotherapy ; Humans ; Interferons - pharmacology ; Interferons - therapeutic use ; Liver Neoplasms - drug therapy ; Liver Neoplasms - pathology ; Medical sciences ; Pharmacology. Drug treatments ; Prospective Studies ; Retrospective Studies ; Risk Factors ; Treatment Outcome</subject><ispartof>Alimentary pharmacology & therapeutics, 2001-05, Vol.15 (5), p.689-698</ispartof><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4429-aeeab42b8192868d6f37b73c92f366a0111875042a6623f81ea4453a815e36f63</citedby><cites>FETCH-LOGICAL-c4429-aeeab42b8192868d6f37b73c92f366a0111875042a6623f81ea4453a815e36f63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1365-2036.2001.00979.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1365-2036.2001.00979.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=969941$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11328263$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Papatheodoridis, G. V.</creatorcontrib><creatorcontrib>Papadimitropoulos, V. C.</creatorcontrib><creatorcontrib>Hadziyannis, S. J.</creatorcontrib><title>Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus‐related cirrhosis: a meta‐analysis</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Background:
The role of interferon in the prevention of hepatocellular carcinoma remains controversial.
Aim:
In this meta‐analysis we evaluated the hepatocellular carcinoma incidence in interferon‐treated and ‐untreated patients with hepatitis C virus‐related cirrhosis.
Methods:
Eleven studies with 2178 patients were found to fulfil our inclusion criteria. The pooled odds ratio (OR) and 95% confidence intervals (CI) were calculated from the raw study data.
Results:
Hepatocellular carcinoma development was significantly more frequent in untreated (21.5%) than in interferon‐treated patients (8.2%; OR: 3.0, 95% CI: 2.3–3.9). In the five studies reporting hepatocellular carcinoma incidence in patients with and without sustained response to interferon, hepatocellular carcinoma was detected at a much higher rate in patients without (9%) than with a sustained response (0.9%; OR: 3.7, 95% CI: 1.7–7.8). Moreover, hepatocellular carcinoma developed significantly more frequently in the untreated patients than in the non‐sustained responders (OR: 2.7, 95% CI: 1.9–3.9). The benefit from interferon on hepatocellular carcinoma incidence was not influenced by the study type (prospective or retrospective), the follow‐up duration, or the study origin.
Conclusions:
Interferon therapy significantly reduces the hepatocellular carcinoma risk in patients with hepatitis C virus cirrhosis. Hepatocellular carcinoma development becomes almost negligible among sustained responders, but a reduction in hepatocellular carcinoma incidence is also achieved even in the non‐sustained responders.</description><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Chemotherapy</subject><subject>Humans</subject><subject>Interferons - pharmacology</subject><subject>Interferons - therapeutic use</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - pathology</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Treatment Outcome</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUtuFDEQhi0EIkPgCsgSErtu_Oh224hNNAoPKRIswtqq8ZQ1HvVjsLuTzI4jsOGCOUnc6VHYsqpS_V9VqeonhHJWclapD_uSS1UXgklVCsZ4yZhpTHn3jKyehOdkxYQyhdBcnpFXKe0ZY6ph4iU541wKLZRckb-X3qMb6eBp6EeMHuPQ03GHEQ5HuqR0izfYDocO-0dwhwcYB4dtO7UQqYPoQj90kCfQrISMJXobxt1ChjEkuqY3IU7p_vefiC2MuKUuxLgbUkgfKdAOR8ga9NAec-k1eeGhTfjmFM_Jz8-X1-uvxdX3L9_WF1eFqyphCkCETSU2mhuhld4qL5tNI50RXioFjHOum5pVApQS0muOUFW1BM1rlMoreU7eL3MPcfg1YRptF9J8GPQ4TMk2TEtdK5NBvYAuDilF9PYQQwfxaDmzsyV2b-fP2_nzdrbEPlpi73Lr29OOadPh9l_jyYMMvDsBkBy0PkLvQnrijDKm4pn6tFC3ocXjf6-3Fz-ucyIfAIBAqwM</recordid><startdate>200105</startdate><enddate>200105</enddate><creator>Papatheodoridis, G. V.</creator><creator>Papadimitropoulos, V. C.</creator><creator>Hadziyannis, S. J.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200105</creationdate><title>Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus‐related cirrhosis: a meta‐analysis</title><author>Papatheodoridis, G. V. ; Papadimitropoulos, V. C. ; Hadziyannis, S. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4429-aeeab42b8192868d6f37b73c92f366a0111875042a6623f81ea4453a815e36f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Chemotherapy</topic><topic>Humans</topic><topic>Interferons - pharmacology</topic><topic>Interferons - therapeutic use</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - pathology</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Papatheodoridis, G. V.</creatorcontrib><creatorcontrib>Papadimitropoulos, V. C.</creatorcontrib><creatorcontrib>Hadziyannis, S. J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Papatheodoridis, G. V.</au><au>Papadimitropoulos, V. C.</au><au>Hadziyannis, S. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus‐related cirrhosis: a meta‐analysis</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2001-05</date><risdate>2001</risdate><volume>15</volume><issue>5</issue><spage>689</spage><epage>698</epage><pages>689-698</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Background:
The role of interferon in the prevention of hepatocellular carcinoma remains controversial.
Aim:
In this meta‐analysis we evaluated the hepatocellular carcinoma incidence in interferon‐treated and ‐untreated patients with hepatitis C virus‐related cirrhosis.
Methods:
Eleven studies with 2178 patients were found to fulfil our inclusion criteria. The pooled odds ratio (OR) and 95% confidence intervals (CI) were calculated from the raw study data.
Results:
Hepatocellular carcinoma development was significantly more frequent in untreated (21.5%) than in interferon‐treated patients (8.2%; OR: 3.0, 95% CI: 2.3–3.9). In the five studies reporting hepatocellular carcinoma incidence in patients with and without sustained response to interferon, hepatocellular carcinoma was detected at a much higher rate in patients without (9%) than with a sustained response (0.9%; OR: 3.7, 95% CI: 1.7–7.8). Moreover, hepatocellular carcinoma developed significantly more frequently in the untreated patients than in the non‐sustained responders (OR: 2.7, 95% CI: 1.9–3.9). The benefit from interferon on hepatocellular carcinoma incidence was not influenced by the study type (prospective or retrospective), the follow‐up duration, or the study origin.
Conclusions:
Interferon therapy significantly reduces the hepatocellular carcinoma risk in patients with hepatitis C virus cirrhosis. Hepatocellular carcinoma development becomes almost negligible among sustained responders, but a reduction in hepatocellular carcinoma incidence is also achieved even in the non‐sustained responders.</abstract><cop>Oxford UK</cop><pub>Blackwell Science Ltd</pub><pmid>11328263</pmid><doi>10.1046/j.1365-2036.2001.00979.x</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2001-05, Vol.15 (5), p.689-698 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70838569 |
| source | MEDLINE; IngentaConnect Free/Open Access Journals; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Antineoplastic agents Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Biological and medical sciences Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - pathology Chemotherapy Humans Interferons - pharmacology Interferons - therapeutic use Liver Neoplasms - drug therapy Liver Neoplasms - pathology Medical sciences Pharmacology. Drug treatments Prospective Studies Retrospective Studies Risk Factors Treatment Outcome |
| title | Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus‐related cirrhosis: a meta‐analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T23%3A54%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20interferon%20therapy%20on%20the%20development%20of%20hepatocellular%20carcinoma%20in%20patients%20with%20hepatitis%20C%20virus%E2%80%90related%20cirrhosis:%20a%20meta%E2%80%90analysis&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Papatheodoridis,%20G.%20V.&rft.date=2001-05&rft.volume=15&rft.issue=5&rft.spage=689&rft.epage=698&rft.pages=689-698&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1046/j.1365-2036.2001.00979.x&rft_dat=%3Cproquest_cross%3E70838569%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70838569&rft_id=info:pmid/11328263&rfr_iscdi=true |